Menu
Recruiting NCT07067268

Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy

Phase II Interventional Nasopharyngeal Cancinoma (NPC)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Adjuvant therapy.
Who it may be relevant to
Registry conditions: Nasopharyngeal Cancinoma (NPC). Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Multicenter, Randomized Controlled, Phase II Trail of Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA After Radiotherapy

Overview

This study aims to explore the efficacy and safety of tislelizumab combined with capecitabine in nasopharyngeal carcinoma patients with residual plasma EBV DNA after radiotherapy.

Interventions

  • Drug Adjuvant therapy
    Tislelizumab: 200 mg IV on day 1, every 3 weeks Capecitabine: 1000 mg/m² orally twice daily on days 1-14，every 3 weeks Treatment duration: 8 cycles

Primary outcome measures

  • Progression-free survival [Time frame: 3 years]
Secondary outcome measures (2)
  • Overall survival [Time frame: 3 years]
  • Toxicities [Time frame: 3 years]

Eligibility criteria

Inclusion criteria

  • Age ≥18 years;
  • Histologically confirmed nasopharyngeal carcinoma;
  • Expected survival time ≥12 weeks;
  • ECOG performance status: 0-1;
  • Received definitive radiotherapy (± induction and/or concurrent chemotherapy);
  • Plasma EBV DNA >0 copies/mL within the period from 1 week before to 4 weeks after completion of radiotherapy ;
  • Adequate organ function meeting the following criteria: Hematological: a. Hemoglobin (HB) ≥90 g/L; b. Absolute neutrophil count (ANC) ≥1.0×10⁹/L; c. Platelet count (PLT) ≥80×10⁹/L; Biochemical: a. Total bilirubin (BIL) <1.5× upper limit of normal (ULN); b. ALT and AST <2.5×ULN; c. Serum creatinine (Cr) ≤ULN, and creatinine clearance rate ≥50 mL/min (calculated by Cockcroft-Gault formula); d. Normal myocardial enzymes and thyroid function; e. Normal cardiac function assessed by echocardiography.
  • Signed informed consent with willingness to comply with the study protocol.

Exclusion criteria

  • Histologically confirmed keratinizing squamous cell carcinoma (WHO I)；
  • Distant metastasis detected by pre-treatment clinical or imaging examinations;
  • History of allergy to any component of monoclonal antibodies, tislelizumab, or capecitabine;
  • History of autoimmune diseases, except for the following conditions (eligible after evaluation):
  • Autoimmune-related hypothyroidism on stable thyroid hormone replacement therapy;
  • Type I diabetes mellitus under stable insulin therapy with controlled blood glucose;
  • Previous or concurrent malignancies (except those cured and disease-free for >5 years, e.g., basal cell carcinoma, cervical carcinoma in situ);
  • Positive pregnancy test in women of childbearing potential;
  • Concurrent medical conditions that may compromise patient enrollment or safety during the study;
  • History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia, idiopathic pneumonia, or other active pulmonary diseases;
  • Active psychiatric disorders or other mental conditions affecting informed consent comprehension;
  • Uncontrolled active infections, including tuberculosis, hepatitis B (HBsAg+), hepatitis C, or HIV (HIV antibody+);
  • Significant cardiovascular diseases: NYHA Class II or higher, myocardial infarction within 1 year, unstable angina, or supraventricular/ventricular arrhythmias requiring clinical intervention;
  • Factors affecting drug administration, distribution, metabolism, or excretion (e.g., psychiatric/neurological disorders, chronic diarrhea, ascites, pleural effusion);
  • Unwillingness to sign informed consent.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • Fudan Universtiy Shanghai Cancer Centre — Shanghai

Identifiers

NCT: NCT07067268 · BioNPC-03

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗